Equibles does not estimate personal net worth.
Earlier roles on record: CEO at Staar Surgical Co (STAA) until December 31, 2022. Staar Surgical Co reported in an 8-K filed December 19, 2022 that Caren Mason retired as member of the Company’s Board of Directors, effective December 31, 2022. Staar Surgical Co reported in an 8-K filed December 19, 2022 that Caren Mason retired as President and Chief Executive Officer, effective December 31, 2022. The proxy statement of Staar Surgical Co reports total compensation of $6,501,953 for Caren Mason in fiscal 2022, including a base salary of $852,318. Disclosed compensation is on record for 6 fiscal years. Caren Mason has spoken on 8 earnings calls across 1 company, most recently for Staar Surgical Co on August 10, 2022. The companies whose calls Caren Mason spoke on are classified in the Healthcare sector.
“On December 16, 2022, STAAR Surgical Company (the “Company”) announced that Ms. Caren Mason, President and Chief Executive Officer of the Company, has elected to retire as CEO and a member of the Company’s Board of Directors (the “Board”), effective December 31, 2022, after seven years successfully leading the Company.”
“On December 16, 2022, STAAR Surgical Company (the “Company”) announced that Ms. Caren Mason, President and Chief Executive Officer of the Company, has elected to retire as CEO and a member of the Company’s Board of Directors (the “Board”), effective December 31, 2022, after seven years successfully leading the Company.”
“The second quarter results we reported today represent a record level of quarterly sales for STAAR at $81.1 million, which represents a 30% year-over-year sales growth and considerable progress in advancing our EVO ICL family of lenses.”
“The first quarter results we reported today represent another quarter of record sales, record ICL units, and profitable growth as we successfully raise awareness and enthusiasm for the visual freedom provided by our EVO family of lenses.”
“The fourth quarter results we reported today are consistent with the preliminary results we announced last month. Fourth quarter results contributed to another record year of sales, profit, cash flow and growth achievements for STAAR in fiscal 2021.”
“I am pleased to report that we experienced outstanding demand for our ICLs during the third quarter and achieved net sales above the high end of our previously provided outlook.”
“This afternoon we reported record results for the second quarter of 2021 as business momentum in all of our major markets globally accelerated from the already robust levels in the second half of 2020, and the record-breaking levels we reported to you on our call for the first quarter of 2021.”
Start not stated–2022-12-31
STAA
Medical Instruments & Supplies · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Staar Surgical Co (STAA) | Former President and Chief Executive Officer | $852,318 | $6,501,953 |
| 2021 | Staar Surgical Co (STAA) | Former President and Chief Executive Officer | $722,463 | $5,468,270 |
| 2020 | Staar Surgical Co (STAA) | Former President and Chief Executive Officer | $667,235 | $2,975,812 |
| 2019 | Staar Surgical Co (STAA) | President and Chief Executive Officer | $626,895 | $3,616,037 |
| 2018 | Staar Surgical Co (STAA) | President and Chief Executive Officer | $585,312 | $2,627,201 |
| 2017 | Staar Surgical Co (STAA) | President and Chief Executive Officer | $562,800 | $1,866,011 |
